Entropy Technologies LP Sells 22,420 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Entropy Technologies LP reduced its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 71.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,780 shares of the biopharmaceutical company's stock after selling 22,420 shares during the period. Entropy Technologies LP's holdings in TG Therapeutics were worth $264,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. NBC Securities Inc. increased its holdings in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 485 shares in the last quarter. Blue Trust Inc. raised its position in TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 849 shares during the last quarter. Values First Advisors Inc. bought a new position in TG Therapeutics in the 3rd quarter valued at $58,000. Synergy Asset Management LLC acquired a new position in TG Therapeutics in the fourth quarter worth $75,000. Finally, GAMMA Investing LLC grew its holdings in shares of TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 2,171 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Trading Down 0.1 %

Shares of NASDAQ:TGTX traded down $0.02 during midday trading on Monday, hitting $30.71. The company had a trading volume of 1,179,306 shares, compared to its average volume of 2,274,709. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12 month low of $12.84 and a 12 month high of $36.84. The firm has a fifty day simple moving average of $31.11 and a 200 day simple moving average of $27.50. The stock has a market cap of $4.78 billion, a price-to-earnings ratio of -307.07 and a beta of 2.26.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 10.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TGTX. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. StockNews.com cut shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, January 31st. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. Finally, TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.